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Background: Kidney disease remains a major cause of morbidity and mortality in Canada and worldwide. New medical
treatments are needed to reduce the progression of kidney disease to improve patient outcomes. C-peptide is normally
released by pancreatic beta-cells along with insulin in healthy individuals, and has been shown to have intrinsic biological
activity and to potentially be renoprotective. The effect of exogenous C-peptide on kidney structure and function, and
the role of C-peptide in the treatment of kidney disease have not yet been fully elucidated.
Methods/Design: We will conduct a systematic review of the literature in human clinical trials and mammalian
experimental models to ascertain the current evidence for the role of C-peptide as a potential therapeutic agent for the
treatment of kidney disease. We aim to identify whether exogenously delivered C-peptide has an effect on clinically
relevant outcomes such as glomerular filtration rate, proteinuria, kidney histology, requirement of renal replacement
therapy, and mortality. We will search MEDLINE, EMBASE, and the Cochrane Central Databases for human or animal
studies in which C-peptide was administered and renal endpoints were subsequently measured. Study quality will be
assessed using the Cochrane Collaboration’s tool for assessing risk of bias. If appropriate, a meta-analysis will be
performed as per standard techniques.
Discussion: The results of this study will determine the potential role of C-peptide as a therapeutic intervention for
patients with kidney disease and will help guide subsequent clinical trials. The study may also provide insight into
which patients or disease states are likely to benefit the most from C-peptide.
Systematic review registration: PROSPERO CRD42014007472
Keywords: C-peptide, Proinsulin, Chronic kidney disease, Diabetes, Systematic reviewBackground
Chronic kidney disease (CKD) is a growing international
healthcare problem. Approximately 13% of North Americans
are estimated to have CKD, a prevalence that is higher
than populations in Europe, Asia, and Australia [1,2].
The presence of CKD is associated with increased mor-
bidity, mortality, and healthcare costs [3]. Current clin-
ical guidelines recommend a multifactorial approach to
CKD, targeted towards risk factor and lifestyle modification,
optimal control of blood pressure and blood sugar, reduc-
tion in proteinuria, and management of the metabolic* Correspondence: gknoll@ottawahospital.on.ca
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unless otherwise stated.sequelae of CKD [4,5]. Although a major objective of this
clinical management strategy is to slow or prevent progres-
sion to end-stage renal disease (ESRD), this is unavoidable
in many cases and results in the requirement for renal re-
placement therapies, which are associated with adverse out-
comes [6]. Thus, there is a need for additional therapies for
the management of kidney diseases to not only reduce the
risk of progression to ESRD, but improve patient outcomes
overall.
A central and accepted paradigm for insulin biosyn-
thesis is the transcription and translation of the INS
gene from chromosome 11 that generates a 110 amino
acid polypeptide termed preproinsulin [7]. The subse-
quent post-translational modification of this molecule
results in an intermediate molecule called proinsulin,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Shaw et al. Systematic Reviews 2014, 3:43 Page 2 of 5
http://www.systematicreviewsjournal.com/content/3/1/43which is then processed and split into insulin and C-
peptide that are both released into the circulation in equi-
molar amounts from pancreatic beta cells [8-10]. C-peptide
was initially thought of as a necessary yet biologically inert
by-product of this process, but has retained clinical utility
as a semi-quantitative marker of insulin secretion [10]. As
examples, measurement of circulating C-peptide levels is
useful in the management of diabetic patients to determine
residual beta cell function, in pancreas or islet cell trans-
plant patients to determine graft function, and in the
workup of patients with hypoglycemia.
In contrast to the clinical role of C-peptide as a marker
of endogenous insulin secretion, there are studies that sup-
port biological activity of C-peptide [11]. Importantly, some
studies have suggested that C-peptide has renoprotective
properties. Observational studies of patients with diabetes
mellitus type 1 or 2 have correlated higher C-peptide levels
with decreased prevalence of microvascular complications
including diabetic nephropathy [12-15], reviewed in [16].
Furthermore, patients with type 1 diabetes have shown im-
proved renal function following pancreas transplant, a pro-
cedure that repletes both C-peptide and insulin from
transplanted beta cells [17,18]. Finally, small trials in which
C-peptide was administered to experimental subjects with
type 1 diabetes have also shown that C-peptide may im-
prove renal function in these patients independent of any
potential effect on glycemic control [19,20]. However, the
therapeutic potential of C-peptide for patients with diabetic
kidney disease remains incompletely understood. Whether
the potential benefit of C-peptide is limited to patients with
diabetes, or is applicable to a broader group of patients is
currently unknown.
Methods/design
Rationale, objectives, and type of studies
The purpose of this systematic review is to synthesize
available data from human and animal experiments, spe-
cifically examining the impact of exogenous C-peptide on
markers of kidney function compared to control, without
the limitation of a particular etiology of kidney disease.
Information sources and search strategy
The electronic databases MEDLINE, EMBASE, and the
Cochrane Central databases will be searched using standard
controlled vocabulary (MeSH or EMTREE), text words,
and keywords. The search will be intentionally broad to be
as sensitive as possible and not to miss any relevant studies
(see Appendix 1 for the full search strategy). An informa-
tion specialist with previous systematic review experience
will be consulted regarding the search strategy.
Article selection
All titles and abstracts resulting from our initial search
will be screened independently by two reviewers. Titleswithout abstracts will have the full text reviewed unless
the article can be clearly excluded based on the informa-
tion provided. Following reconciliation of differences be-
tween reviewers, the full text of the selected articles will
be completely screened by each reviewer independently.
During this process, a final decision for inclusion or exclu-
sion will be made according to the criteria below. Any dis-
crepancies will be resolved by a third party.
Inclusion and exclusion criteria
Peer-reviewed published articles will be included if they
meet all of the following criteria:
1. The experimental subjects are either humans or
other mammals of any age;
2. The study intervention involves the administration
of exogenous C-peptide to subjects;
3. The reported outcomes are related to relevant
markers of kidney function, kidney disease,
requirement for renal replacement therapy, or
mortality; and
4. The manuscript must be written in English.
Studies using purified, artificial, recombinant, synthetic,
or long acting formulations of C-peptide will be included
for analysis. C-peptide from any species will be acceptable
for inclusion.
Single case reports, narrative reviews, and studies report-
ing exclusively in vitro cell culture experiments, or ex vivo
experiments will be excluded. We will also exclude studies
in which animals or humans were given C-peptide, but the
results contain only cellular or molecular endpoints such as
change in gene expression profile, change in protein or en-
zyme concentration or activity, or cellular viability. There
will be no limits on study publication date, other study de-
sign parameters, or sample size.
Data collection process
Full text of all included articles will be electronically saved
and each article will be assigned a unique code. Reference
lists will be manually reviewed for other potentially eligible
articles. In each included article, we will use a standardized
form to collect information pertaining to:
1. Study design, methods, and timing of C-peptide
administration;
2. Characteristics of experimental subjects;
3. C-peptide type and dosing;
4. Relevant renal outcomes such as glomerular
filtration rate (GFR), serum creatinine, proteinuria/
albuminuria, hematuria, renal blood flow, urine
electrolyte excretion, kidney size, requirements for
renal replacement therapy, and kidney histologic
parameters;
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hemodynamic parameters (including blood pressure),
cardiovascular risk, stroke risk, and mortality;
6. Study funding sources; and
7. Information necessary for risk of bias assessment.
Quality assessment
Any randomized controlled trials that are included will
be assessed for bias using the Cochrane Collaboration’s
tool for assessing risk of bias.
Data synthesis and analysis
Human and animal studies will be analyzed separately.
Additionally, because it is anticipated that kidney func-
tion in diabetes will be the most well studied model
among the search results, diabetic nephropathy studies
will be analyzed separately from studies looking at other
types of kidney disease.
We anticipate several sources of heterogeneity among
our final dataset, particularly among the animal studies
since we expect variation in disease model employed,
methodology including experimental timing, and differ-
ences in chosen outcomes of interest. In particular, the
C-peptide dose, route, and duration of administration
may vary considerably between studies. For studies that
have comparable methodology and outcomes, we will
pool the results using a random-effects model for con-
tinuous or categorical variables as appropriate. In situa-
tions where data cannot be pooled, a narrative synthesis
will be provided.
The current evidence for a therapeutic role of C-peptide
in the context of kidney disease will be summarized based
on the results of the search. The potential future clinical
use of C-peptide will be discussed, along with suggested
further research directions.
Discussion
The aim of this systematic review is to ascertain the current
evidence for and against the notion that exogenous delivery
of proinsulin C-peptide has a potential beneficial effect on
parameters of renal function. The rigorous and systematic
nature of our review will ensure that it includes the best
available information. Effort will be made to identify and
limit procedural sources of bias and data heterogeneity.
Because the therapeutic use of C-peptide is still in an
early experimental stage we have purposely decided to
keep the search strategy and study inclusion criteria rela-
tively broad in order to capture a comprehensive under-
standing of the potential therapeutic use for C-peptide in
patients with kidney disease of any etiology. Although it is
anticipated that most included studies will focus on
models of CKD, we will not exclude studies looking at the
role of C-peptide in the treatment of acute kidney injury
(AKI) if they exist, so long as they meet eligibility criteria.Our review may be limited by the number of available
studies in the literature. As such, we have intentionally in-
cluded both human and other mammalian studies to de-
termine if a biological effect or signal for C-peptide truly
exists. The added benefit of this is that other mechanisms
of kidney injury may be tested against C-peptide adminis-
tration in animal models that have not been considered
for human trial at present, and may identify further areas
of research.
We have elected to exclude studies in which C-peptide
was given to whole animals, but reported results pertain
only to changes in gene or protein expression, enzyme ac-
tivity, or other cellular or molecular endpoints. The ration-
ale for this exclusion is two-fold. First, we only wish to
include studies that directly examine gross organ structure
and function per se, to facilitate clinical interpretation of
the potential therapeutic utility of C-peptide. In the context
of this review we view genetic and molecular-based end-
points as mechanistic in nature. Although these studies
serve the important role of furthering our understanding of
the underlying processes leading to changes in organ struc-
ture and function, that level of detail is outside the scope of
our research question. Second, inclusion of these studies
would increase the heterogeneity of the pooled results since
we anticipate different investigators will be looking at differ-
ent genes, proteins, and signal transduction pathways.
Overall, our decision to look at only human and in vivo
mammalian studies was made to make the results of our
study applicable to clinical practice and future clinical re-
search as much as possible.
All medical interventions carry some degree of risk.
Accordingly, our data extraction will also include rele-
vant non-renal endpoints pertaining to hemodynamics
(for example, blood pressure), glycemic control, cardio-
vascular risk, stroke risk, and mortality, if reported, to
assess for any evidence of adverse events with C-peptide
administration.
The results of this study will determine the potential
role of C-peptide as a therapeutic intervention for pa-
tients with kidney disease, which will help guide subse-
quent clinical trials. The study may also provide insight
into which patients or disease states are likely to benefit
the most from C-peptide.
Appendix 1: Search strategy
Database: Embase Classic + Embase <1947 to 2014 January
17>, Ovid MEDLINE(R) In-Process & Other Non-Indexed





4. exp kidney diseases/(1123898)
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12. renal insufficiency.tw. (46280)
13. ((impair$ or damage$ or injur$) adj2
(renal or kidney)).tw. (95922)
14. exp proteinuria/(100535)
15. proteinuria.tw. (67668)
16. exp kidney function tests/(76360)
17. (glomerular filtration rate or glomerulus filtration
rate or GFR).tw. (74821)
18. blood urea nitrogen.tw. (16036)
19. ((kidney or renal) adj3 (renogra$ or angio$ or
scinti$)).tw. (22169)
20. exp Kidney/(720592)
21. (kidney size or kidney mass).tw. (2038)
22. ((small$ or large$) adj2 kidne$).tw. (6099)
23. exp biopsy/and (kidney or renal).tw. (56542)
24. ((kidney or renal) adj2 biopsy).tw. (28834)
25. or/4-24 (1767311)
26. 3 and 25 (1952)




31. exp kidney disease/(1123898)







39. renal insufficiency.tw. (46280)
40. ((impair$ or damage$ or injur$) adj2
(renal or kidney)).tw. (95922)
41. exp proteinuria/(100535)
42. proteinuria.tw. (67668)
43. exp glomerulus filtration rate/(53592)
44. (glomerular filtration rate or glomerulus filtration
rate or GFR).tw. (74821)
45. blood urea nitrogen.tw. (16036)
46. exp kidney function/(167997)
47. exp kidney size/(1888)
48. exp kidney mass/(3215)
49. exp kidney examination/(61135)
50. exp kidney/(720592)
51. ((kidney or renal) adj3 (renogra$ or angio$ or
scinti$)).tw. (22169)
52. (kidney size or kidney mass).tw. (2038)53. ((small$ or large$) adj2 kidney$).tw. (6099)
54. ((kidney or renal) adj2 biopsy).tw. (28834)
55. or/31-54 (1797601)
56. 30 and 55 (2165)
57. 56 use emczd (1469)
58. 27 or 57 (2196)
59. limit 58 to english language (2005)
60. remove duplicates from 59 (1560)
Database: EBM Reviews – Cochrane Database of Sys-
tematic Reviews <2005 to December 2013>, EBM Re-
views – ACP Journal Club <1991 to December 2013>,
EBM Reviews – Database of Abstracts of Reviews of
Effects <4th Quarter 2013>, EBM Reviews – Cochrane Cen-
tral Register of Controlled Trials <December 2013>, EBM
Reviews – Cochrane Methodology Register <3rd Quarter
2012>, EBM Reviews – Health Technology Assessment <4th
Quarter 2013>, EBM Reviews – NHS Economic Evaluation
Database <4th Quarter 2013>
Search Strategy:
1. c-peptide.mp. (1810)







9. renal insufficiency.mp. (1751)
10. ((impair$ or damage$ or injur$) adj2 (renal or
kidney)).mp. (2725)
11. proteinuria.mp. (2142)
12. (glomerular filtration rate or glomerulus filtration
rate of GFR).mp. (3171)
13. blood urea nitrogen.mp. (891)
14. ((kidney or renal) adj3 (renogra$ or angio$
or scinti$)).mp. (713)
15. kidney.mp. (19171)
16. (kidney size or kidney mass).mp. (18)
17. ((small$ or large$) adj2 kidney$).mp. (43)
18. ((kidney or renal) adj2 biopsy).mp. (286)
19. or/2-18 (25977)
20. 1 and 19 (82)
21. limit 20 to english language [Limit not valid in CDSR,
ACP Journal Club,DARE,CCTR,CLCMR; records were
retained] (82)
22. remove duplicates from 21 (82)
Abbreviations
AKI: Acute kidney injury; CKD: Chronic kidney disease; ESRD: End-stage renal
disease; GFR: Glomerular filtration rate.
Competing interests
The authors declare that they have no competing interests.
Shaw et al. Systematic Reviews 2014, 3:43 Page 5 of 5
http://www.systematicreviewsjournal.com/content/3/1/43Authors’ contributions
JS conceived of the study. The review was designed by JS, PS, and GK. JS
drafted the manuscript. GK and KB provided content and methodological
expertise, feedback, and critical comments on the overall study design, protocol,
and manuscript. All authors read and approved the final manuscript.
Acknowledgments
We thank Risa Shorr, an information specialist, for her help and support in
constructing the search strategy.
Received: 21 March 2014 Accepted: 23 April 2014
Published: 2 May 2014
References
1. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, Badawi A:
Prevalence estimates of chronic kidney disease in Canada: results of a
nationally representative survey. Can Med Assoc J 2013, 185:E417–E423.
2. Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P, Van Lente F, Levey A:
Prevalence of chronic kidney disease in the United States. JAMA 2007,
298:2038–2047.
3. Honeycutt A, Segel J, Zhuo X, Hoerger T, Imai K, Williams D: Medical costs
of CKD in the Medicare population. J Am Soc Nephrol 2013, 24:1478–1483.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group:
KDIGO clinical practice guideline for the evaluation and management of
chronic kidney disease. Kidney Int Suppl 2013, 3:1–150.
5. National Kidney F: KDOQI Clinical Practice Guideline for Diabetes and
CKD: 2012 Update. Am J Kidney Dis 2012, 60:850–886.
6. Williams ME: Diabetic CKD/ESRD 2010: a progress report? Semin Dial 2010,
23:129–133.
7. Chan SJ, Keim P, Steiner DF: Cell-free synthesis of rat preproinsulins:
characterization and partial amino acid sequence determination.
Proc Natl Acad Sci U S A 1976, 73:1964–1968.
8. Steiner DF, Cunningham D, Spigelman L, Aten B: Insulin biosynthesis:
evidence for a precursor. Science 1967, 157:697–700.
9. Clark JL, Steiner DF: Insulin biosynthesis in the rat: demonstration of two
proinsulins. Proc Natl Acad Sci U S A 1969, 62:278–285.
10. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH: Proinsulin,
insulin, and C-peptide concentrations in human portal and peripheral
blood. J Clin Invest 1975, 55:1278–1283.
11. Wahren J, Ekberg K, Jornvall H: C-peptide is a bioactive peptide.
Diabetologia 2007, 50:503–509.
12. Bo S, Gentile L, Castiglione A, Prandi V, Canil S, Ghigo E, Ciccone G:
C-peptide and the risk for incident complications and mortality in type 2
diabetic patients: a retrospective cohort study after a 14-year follow-up.
Eur J Endocrinol 2012, 167:173–180.
13. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G,
Cavallo Perin P, Bruno G: Fasting plasma C-peptide and micro- and
macrovascular complications in a large clinic-based cohort of type 1
diabetic patients. Diabetes Care 2009, 32:301–305.
14. Kim B-Y, Jung C-H, Mok J-O, Kang S-K, Kim C-H: Association between
serum C-peptide levels and chronic microvascular complications in
Korean type 2 diabetic patients. Acta Diabetol 2012, 49:9–15.
15. Zheng WC, Chen L: Factor analysis of diabetic nephropathy in Chinese
patients. Diabetes Metab Syndr 2011, 5:130–136.
16. Luppi P, Kallas A, Wahren J: Can C-peptide mediated anti-inflammatory
effects retard the development of microvascular complications of type 1
diabetes? Diabetes Metab Res 2013, 29:357–362.
17. Boggi U, Vistoli F, Amorese G, Giannarelli R, Coppelli A, Mariotti R, Rondinini L,
Barsotti M, Piaggesi A, Tedeschi A, Signori S, De Lio N, Occhipinti M, Mangione
E, Cantarovich D, Del Prato S, Mosca F, Marchetti P: Results of pancreas
transplantation alone with special attention to native kidney function and
proteinuria in type 1 diabetes patients. Rev Diabet Stud 2011, 8:259–267.
18. Cantarovich D, Perrone V: Pancreas transplant as treatment to arrest renal
function decline in patients with type 1 diabetes and proteinuria.
Semin Nephrol 2012, 32:432–436.19. Johansson B, Kernell A, Sjoberg S, Wahren J: Influence of combined
C-peptide and insulin administration on renal function and metabolic
control in diabetes type 1. J Clin Endocrinol Metab 1993, 77:976–981.
20. Johansson B, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J:
Beneficial effects of C-peptide on incipient nephropathy and neuropathy
in patients with Type 1 diabetes mellitus. Diabetic Med 2000, 17:181–189.
doi:10.1186/2046-4053-3-43
Cite this article as: Shaw et al.: The therapeutic potential of C-peptide in
kidney disease: a protocol for a systematic review and meta-analysis.
Systematic Reviews 2014 3:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
